MINNEAPOLIS (Oct. 3, 2016) – The Minnesota High Tech Association (MHTA) has named OneOme as a finalist in the Healthcare – Small and Growing category for the 2016 Tekne Awards, which will be held at the Minneapolis Convention Center on Wednesday, Nov. 16. The Tekne Awards honor Minnesota companies and individuals who have shown superior technology innovation and leadership.
OneOme, a Twin Cities-based company, has developed the RightMed™ test, a cost-effective, personalized pharmacogenomic analysis of 22 genes provided as part of routine clinical care. The test, clinical report, and interactive online tool help healthcare providers make timely, evidence-based prescription treatment decisions across more than 340 medications. OneOme has also developed an interpretive only report product for those clients who provide their own genotype or sequence data.
“The Tekne Awards are an important way for OneOme to be recognized,” said Paul Owen, CEO of OneOme. “Precision medicine is rapidly growing, and understanding how we as individuals respond to prescription drugs based on our DNA can significantly alter our approach to healthcare treatment options.”
Presented by the MHTA, the Tekne Awards annually recognize Minnesota’s best and brightest technology users and developers in innovation, development, education, commercialization and management. A full list of finalists is available online at http://www.tekneawards.org.
“Each year, MHTA seeks out companies and people leading the way in innovation in Minnesota,” said Margaret Anderson Kelliher, president and CEO of MHTA. “These advancements are changing the way people all over the world live and work, and the Tekne Awards recognize those achievements.”
The 17th annual Tekne Awards program will begin at 4:30 p.m. with a VIP registration and reception, followed by general registration and cocktails at 5 p.m. The awards ceremony will commence at 7 p.m., with a post-event reception at 8:30 p.m. The event will be emceed by Paul Douglas, author, entrepreneur and meteorologist.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme’s RightMed test interpretation is currently in use by Mayo Clinic Center for Individualized Medicine (CIM). OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit www.oneome.com.
About Minnesota High Tech Association (MHTA)
MHTA is an innovation and technology association united in fueling Minnesota’s prosperity. We help bring together the people of Minnesota’s technology ecosystem and lead the charge in directing technology issues to Minnesota’s state capitol. MHTA is the only membership organization that represents Minnesota’s entire technology-based economy. MHTA members include organizations of every size − involved in virtually every aspect of technology creation, production, application and education in Minnesota. Find out more online at http://www.mhta.org or follow MHTA on Twitter athttp://twitter.com/MHTA.
Editor’s Note: Mayo Clinic has financial interest in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.